NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY

NEW DATA OF EXTENSIVE RESEARCH PROGRAM AND THE RESULTS OF STUDIES IN REAL CLINICAL PRACTICE FROM DIFFERENT COUNTRIES REAFFIRMED THE HIGH EFFICACY AND A FAVORABLE SAFETY PROFILE OF RIVAROXABAN (XARELTO®) FROM THE BAYER COMPANY PRESS RELEASE OF THE BAYER COMPANY

.

Bibliographic Details
Main Author: article editorial
Format: Article
Language:English
Published: Stolichnaya Izdatelskaya Kompaniya 2017-01-01
Series:Racionalʹnaâ Farmakoterapiâ v Kardiologii
Online Access:https://www.rpcardio.com/jour/article/view/1386

Internet

https://www.rpcardio.com/jour/article/view/1386

Similar Items